TALKDESK
25.1.2024 17:01:28 CET | Business Wire | Press release
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced its presence at the All4Customer event in Paris from March 26 - 28, 2024. Investment in the event is part of the company’s commitment to the French market and to driving exceptional outcomes for customers and partners across the region with the power of artificial intelligence (AI)-driven customer experience.
Simon Desvergez, enterprise solutions engineer at Talkdesk, will deliver a masterclass on supercharging contact center optimization with generative AI (GenAI) on Wednesday, March 27, 2024 at 12:00 p.m. in Masterclass 6. During the 45-minute session, industry professionals will hear examples of how GenAI has automated complex customer use cases and significantly improved the quality of self-service interactions.
The All4Customer event, which attracts approximately 15,000 attendees, is the latest example of continued commitment from Talkdesk to the French market. Over the past several months, Talkdesk has exhibited at the Customer Relationship and Marketing Meetings (CRM&M) event in Cannes to gain opportunities to meet face-to-face with local customer experience (CX) leaders and held the Talkdesk Partner Academy in Paris as an investment in its partner ecosystem.
Tiago Paiva, founder and chief executive officer at Talkdesk, commented: “France continues to be a significant business driver for the company, and we’re excited for 2024 to drive further local expansion for Talkdesk. All4Customer is an important opportunity for us to connect with local CX leaders in-person and discuss the value that deploying AI cloud technology can unlock in the contact center.”
Customers such as Quadient, a global leader in cloud-based business communication software, parcel locker solutions, and mailing systems technology based in Bagneux, France, uses Talkdesk to deliver frictionless customer interactions. Before implementing Talkdesk, 40% of Quadient’s call volume in some queues consisted of simple transactions that could be self-serviced to reserve agents’ time for more complex tasks. Quadient initially developed its self-service solutions with Talkdesk, then expanded to other Talkdesk tools, including a solution to assist with agent coaching and a voice bot. As a result, Quadient doubled its self-service capabilities, increased efficiency, and created better experiences for customers and agents.
Jackie James, director of global operations at Quadient, said: “The thing that I like about Talkdesk more than anything is that they're constantly looking for ways to improve. They’re regularly deploying features that have positive impacts on CX." As one example of this, James added: “By using a voice bot [to serve Parcel Pending], we could contain a lot of simple transactions just by walking the customer through a few steps and using some integrations with our web application. We immediately saw a 60% containment rate.”
FACYLE, a key partner of Talkdesk in the French market specializing in Consulting and CTI integration, expressed excitement about the ongoing collaboration. As a crucial launch partner, FACYLE has significantly contributed to the success of Talkdesk in France. FACYLE Chief Executive Officer Francois Breuiller highlighted the consistent investment from Talkdesk in the success of their partnership and the French market.
The Talkdesk-FACYLE partnership has led to notable achievements, including successful projects with Groupe APRIL and Groupe Monnoyeur. This success is attributed to dedication from Talkdesk in providing resources, materials, and events tailored for the French audience. These efforts have accelerated momentum, empowering enterprises to enhance customer experiences through the Talkdesk AI-powered contact center solutions.
Francois Breuiller further emphasized the positive impact of the partnership, stating: "Partnering with Talkdesk for the past two years has proven that we made the right choice for a pure CCaaS solution. We successfully implemented their solution on large customers’ projects, showcasing robustness and comprehensive feature coverage.”
The All4Customer event will take place at Paris Expo Porte de Versailles, Pavilion 4, where Talkdesk will exhibit in stand F28. For more information, visit www.all4customer-paris.com.
About Talkdesk
Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do and our investment in the highest levels of security and reliability for our products make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240125676968/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom